Specialist care for Urological Cancers · LucknowTeleconsultation available for patients across India
Meet the Doctor Blogs WhatsApp Us +91-9559776664
Home›Treatments›Prostate Cancer

Prostate Cancer at a Glance

Often silent

Early Prostate Cancer rarely causes symptoms. A rising PSA is usually the first clue.

MRI before biopsy

A prostate MRI helps decide whether a biopsy is needed, and where to target it.

Not every cancer needs treatment

Low-risk cancers are often best managed with active surveillance.

Function matters

When surgery is needed, nerve-sparing robotic techniques aim to protect continence and erections.

Symptoms and Who Is at Risk

Urinary symptoms in men over 50, such as a weak stream or waking at night to pass urine, are usually caused by benign enlargement of the prostate rather than cancer. Prostate Cancer tends to cause symptoms only when it is advanced. A urological opinion is worthwhile if you have:

  • A PSA above the expected range for your age, or one that keeps rising
  • A nodule or hard area felt on rectal examination
  • Blood in the semen or urine
  • Bone pain, weight loss or leg weakness (these may indicate advanced disease)

Risk factors

The chance of Prostate Cancer rises steadily with age. A father or brother with Prostate Cancer roughly doubles the risk, and inherited changes in the BRCA2 gene are linked with more aggressive disease. Men with these risk factors may reasonably start PSA testing in their mid-40s after discussing it with a doctor.

Understanding Your PSA Result

PSA is a protein made by both normal and cancerous prostate cells, so a single number never tells the whole story. Dr. Singh reads a PSA result alongside several other details:

What is looked atWhy it matters
Age-related rangePSA naturally rises as the prostate enlarges with age
PSA densityPSA divided by prostate volume. A large benign prostate makes more PSA, so density separates the two better than PSA alone
Trend over timeA steady rise is more meaningful than one high reading
Free-to-total PSA ratioA low ratio slightly increases the likelihood of cancer
Temporary causesInfection, a recent catheter, ejaculation or cycling in the previous 48 hours can raise PSA

A repeat test after excluding temporary causes is often the sensible first step. You can calculate your PSA density below if your MRI or ultrasound report mentions prostate volume.

How the Diagnosis Is Made

Multiparametric MRI

An MRI of the prostate is now recommended before any biopsy. It is reported with a PI-RADS score from 1 to 5. A score of 4 or 5 usually means a targeted biopsy is needed, while a normal MRI with a low PSA density may allow a biopsy to be avoided altogether.

Transperineal biopsy

Samples are taken through the skin between the scrotum and the anus rather than through the rectum. This route has a much lower risk of serious infection and samples the front of the prostate better. Targeted cores from any MRI lesion are combined with systematic cores from the rest of the gland.

Staging scans

For intermediate- and high-risk cancers, a PSMA PET-CT is the most sensitive test for spread to lymph nodes or bone. A bone scan with CT is an alternative where PSMA PET is not available.

Grade Group and Risk Group

The pathologist grades the cancer using the Gleason score, which is converted into an ISUP Grade Group from 1 (least aggressive) to 5 (most aggressive).

Grade GroupGleason scoreWhat it means
13 + 3 = 6Slow growing; rarely spreads
23 + 4 = 7Mostly low grade with a smaller aggressive component
34 + 3 = 7Mostly the more aggressive pattern
48High grade
59 or 10Highest grade

Grade Group, PSA and the clinical stage are then combined into a risk group, which guides treatment:

Risk groupTypical featuresOptions usually discussed
LowGrade Group 1, PSA below 10, confined to the prostateActive surveillance
Favourable intermediateGrade Group 2 with limited diseaseSurveillance in selected men, robotic prostatectomy or radiation
Unfavourable intermediateGrade Group 3, or several intermediate featuresRobotic prostatectomy, or radiation with short-term hormone therapy
HighGrade Group 4–5, PSA above 20, or disease beyond the capsuleSurgery as part of multimodal care, or radiation with long-term hormone therapy
MetastaticSpread to lymph nodes or boneHormone therapy with newer agents, chemotherapy or PSMA-targeted therapy

Check your risk group or calculate your CAPRA score using the tools below.

Treatment Options

Active surveillance

For low-risk cancer, active surveillance means regular PSA tests, a repeat MRI and, when needed, a repeat biopsy. Treatment is offered only if the cancer shows signs of change. Long-term studies show that this approach is as safe as immediate treatment for suitable men, while sparing many of them the side effects of surgery or radiation.

Robotic radical prostatectomy

The prostate and seminal vesicles are removed through keyhole incisions, with the pelvic lymph nodes when the risk of spread justifies it. It suits men with a good life expectancy and cancer confined to, or just beyond, the prostate.

Radiation therapy

External beam radiotherapy, usually combined with a period of hormone therapy for intermediate- and high-risk disease, gives cancer control comparable to surgery in suitable patients. The side effects are different, affecting the bladder and bowel more than continence.

Advanced disease

When the cancer has spread, treatment is systemic: hormone therapy combined with newer hormonal agents, chemotherapy, or PSMA-targeted radioligand therapy, planned together with medical oncology.

Surgery or radiation? For localised disease, both offer similar cancer control. The choice depends on age, urinary symptoms, bowel health, previous abdominal surgery and personal priorities, and is made after a frank discussion of trade-offs.

What to Expect from Robotic Prostatectomy

  • Before surgery: pelvic floor exercises are started a few weeks in advance, which speeds the return of urinary control.
  • Nerve-sparing: the nerves for erections lie on the surface of the prostate and are preserved on one or both sides when the cancer allows.
  • Hospital stay: most men walk on the day of surgery and go home after 2–3 days.
  • Catheter: a urinary catheter stays for about 7–10 days while the join between bladder and urethra heals.
  • Continence: most men regain control over weeks to a few months; a small number need further treatment.
  • Erections: recovery may take one to two years and is supported with medicines and other treatments.

More about Robotic Surgery.

Follow-Up and Recovery

After surgery, PSA should become undetectable within about six weeks. It is then checked every three to six months for the first few years, and yearly after that. After radiation, PSA falls slowly and is judged against its lowest point.

A rising PSA after treatment is called biochemical recurrence. Its significance depends on how high it is and how fast it is rising. A short PSA doubling time usually prompts a PSMA PET scan and discussion of salvage radiotherapy or systemic treatment.

Urinary control and erectile function are reviewed at every visit using standard questionnaires (IPSS, SHIM and ICIQ), so that recovery can be tracked and supported.

Questions Worth Asking at Your Consultation

  1. What are my Grade Group, PSA density and risk group?
  2. Is active surveillance a safe option for me?
  3. Do I need a PSMA PET scan before deciding?
  4. What are my realistic chances of staying continent and keeping erections after each treatment?
  5. Can nerve-sparing be done on one or both sides?
  6. How will my PSA be followed after treatment?

Frequently Asked Questions

My PSA is high. Does that mean I have Prostate Cancer?

Not necessarily. Benign prostate enlargement, infection, a recent catheter or even cycling can raise PSA. A repeat test and a prostate MRI usually come before any decision about biopsy.

Is active surveillance just waiting for the cancer to grow?

No. It is a structured programme of PSA tests, MRI and repeat biopsy designed to catch any change early. For low-risk cancer it is as safe as immediate treatment and avoids unnecessary side effects.

Why is a transperineal biopsy preferred?

Because the needle passes through the skin rather than the rectum, the risk of serious infection is much lower, and the front of the prostate is sampled more reliably.

How soon can I return to work after robotic prostatectomy?

Most men return to desk work in about three to four weeks, once the catheter is out and energy returns. Heavy lifting is avoided for about six weeks.

Will I need hormone therapy?

Hormone therapy is usually combined with radiation for intermediate- and high-risk disease and is the basis of treatment for spread disease. It is not routinely needed after successful surgery.

Can I take a second opinion before deciding on treatment?

Yes. Prostate Cancer often has more than one reasonable option, and a second opinion is a sensible step before any major decision. Reports can be reviewed in person or by teleconsultation.

Patient Tools

Understand Your Reports

The same validated scores used in clinic. Enter figures from your own reports and bring the results to your consultation.

Results are estimates for groups of patients and do not replace medical advice. Entries stay in your browser and are not stored or sent.

Before and at diagnosis
Patient tool

PSA density

PSA is easier to interpret alongside the size of the prostate, because a larger gland naturally produces more PSA. If your MRI or ultrasound report mentions the prostate volume, you can enter it below to see your PSA density, a figure urologists often consider when deciding whether a biopsy is needed.

Only have the dimensions? Calculate the volume

Ellipsoid formula: length × width × height × 0.52

Enter your PSA and prostate volume.

About this tool

PSA density (PSA ÷ prostate volume) corrects PSA for prostate size, since a large benign prostate makes more PSA. A density of 0.15 ng/mL/cc or higher is commonly used as a threshold for an increased likelihood of clinically significant cancer, and it is especially useful when deciding on biopsy after an equivocal (PI-RADS 3) or negative MRI.

Before a biopsy: external risk calculators

If you are deciding whether to have a prostate biopsy, these research-group calculators estimate the chance that it would find cancer, using PSA, age, examination findings and family history.

Patient tool

Prostate Cancer risk group

After a diagnosis of Prostate Cancer, the PSA, biopsy grade and clinical stage together place the cancer in a risk group, and the treatment options depend largely on this group. With the details from your reports, you can see which group applies to you. This assumes the scans show no spread outside the prostate.

Grade Group (ISUP) on biopsy
Clinical T stage (from examination / MRI; ask your doctor if unsure)
Biopsy cores positive (optional, refines intermediate risk)

Enter PSA, Grade Group and T stage.

About this tool

Simplified from the NCCN Guidelines for Prostate Cancer. Very-low-risk classification (which also uses PSA density and core details) and some very-high-risk criteria (primary Gleason pattern 5, more than 4 cores with Grade Group 4–5) are not separated here. Your doctor will confirm your exact group.

Patient tool

CAPRA score

The CAPRA score combines five details available at diagnosis into one number that estimates the chance of the cancer returning after treatment. It can be a useful reference point when you are comparing treatment options.

Gleason score on biopsy
Clinical T stage
Percentage of biopsy cores positive

Answer all five items.

About this tool

Cooperberg MR et al., J Urol 2005. Score 0–10: 0–2 low, 3–5 intermediate, 6–10 high risk. Each 2-point increase roughly doubles the risk of recurrence. The score has been validated in large cohorts after surgery, radiation and other treatments.

After treatment
Patient tool

PSA doubling time

After surgery or radiation, how quickly the PSA is rising often matters more than any single value. If you have several PSA results, enter them with their dates to see the doubling time. Three or more results taken over at least three months give the most reliable estimate.

Enter at least 2 dated PSA values (3 or more is better).

About this tool

Calculated as ln(2) divided by the slope of a straight line fitted to the natural logarithm of PSA against time, the method used in published nomograms such as MSKCC's. A short doubling time (especially under 3 months, or under about 9–12 months) is associated with a higher risk of metastasis after treatment, while a long doubling time (over 15 months) is generally favourable. Not meaningful while on hormone therapy or soon after starting or stopping it.

Patient tool

Urinary symptom score (IPSS)

Recording urinary symptoms with a standard questionnaire makes it easier to see how they change, both before treatment and during recovery. It takes about two minutes, and you can bring the score to your next visit.

Answer all 7 symptom questions.

About this tool

Barry MJ et al., AUA Symptom Index, J Urol 1992; adopted as the IPSS by WHO. Score 0–7 mild, 8–19 moderate, 20–35 severe. The quality-of-life question is reported separately (0–6).

Patient tool

Erectile function score (SHIM / IIEF-5)

Erectile function is an important part of recovery after prostate treatment, and it often keeps improving for one to two years. This five-question score is the one used in clinics; noting it at each visit helps guide rehabilitation.

Answer all 5 questions.

About this tool

Rosen RC et al., Int J Impot Res 1999. Score 5–25: 22–25 no erectile dysfunction; 17–21 mild; 12–16 mild to moderate; 8–11 moderate; 5–7 severe. After nerve-sparing prostatectomy, erectile recovery often continues for 1–2 years, and treatment (penile rehabilitation) is available.

Patient tool

Urinary leakage score (ICIQ-UI SF)

If you have leakage after prostate surgery or a neobladder, this short questionnaire records how often it happens, how much you leak, and how much it affects daily life. Scores noted over the months show how continence is recovering.

Answer the 3 scored questions.

About this tool

Avery K et al., Neurourol Urodyn 2004. Score 0–21. Severity bands (Klovning et al. 2009): 1–5 slight, 6–12 moderate, 13–18 severe, 19–21 very severe. ICIQ questionnaires © ICIQ Group, reproduced for patient self-assessment.

Patient Experiences

Shared by patients and families treated by Dr. Anshuman Singh.

“

I would like to express my heartfelt gratitude to Dr. Anshuman Singh for the exceptional care and expertise he provided during my prostate cancer treatment. From the very beginning, Dr. Singh demonstrated an outstanding level of professionalism and compassion.

VK
Vinod Kumar BhatPatient
“

Last year on 25th May, 2024, I underwent robotic prostate surgery performed by Dr. Anshuman Singh and I couldn’t be more grateful for the exceptional care and expertise I received. From my very first consultation, Dr. Anshuma took the time to clearly explain my diagnosis, treatment options, and what to expect before, during, and after the surgery.

MG
Malik Girish AnandPatient
“

Dr. Anshuman Singh is an extremely expert and caring doctor. Provided accurate diagnosis and consistent consultations throughout prostate treatment at Medanta. His constant availability and attention made the entire process reliable and comforting.

RC
Radhika ChemicalsPatient

Have a raised PSA or a new diagnosis?

A structured review of your PSA history, MRI and biopsy explains where you stand and what your options are.

WhatsApp +91-9559776664